UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November 13~~January 6, ~~2025~~ 2026

Biohaven Ltd.

(Exact name of registrant as specified in its charter)


British Virgin Islands	001-41477	Not applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol Name of each exchange on which registered Common ~~shares~~Shares, no par value BHVN New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On ~~November~~January 126, ~~2025~~2026, Biohaven Ltd. (the “Company”) ~~entered~~agreed ~~into~~to anissue ~~underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC~~ and ~~Goldman~~sell ~~Sachs & Co. LLC~~12, ~~as representatives of the several underwriters named therein~~500,000 ~~in connection with the registered public offering (the “Offering”) of up to 26,833,334 of the Company’s~~ common shares, ~~including the underwriters’ option~~ to ~~purchase~~Janus ~~3,500,000~~Henderson ~~additional~~Investors ~~common shares,~~ at a purchase price ~~to the public~~ of $710.5000 per ~~common~~ share. OnThe ~~November 13, 2025, the~~ Company ~~issued~~expects ~~and sold 26,833,334 of its common shares pursuant~~ to ~~the~~receive ~~Underwriting~~$125 ~~Agreement,~~million ~~which included the exercise~~ in ~~full of the underwriters’ option to purchase additional common shares. The aggregate~~ gross proceeds toupon ~~the Company from the Offering~~settlement, before deducting ~~underwriting~~fees ~~discounts~~ and ~~commissions~~other ~~and offering~~ expenses payable by ~~the Company, were approximately $200 million~~it.

The ~~Underwriting~~common ~~Agreement~~shares ~~contains~~are ~~customary~~being ~~representations,~~issued ~~warranties~~as ~~and~~a ~~agreements~~block oftransaction under the Company,’s ~~conditions~~“at-the-market” tooffering ~~closing~~program, ~~indemnification~~which ~~rights~~has ~~and~~been ~~obligations~~registered under the Securities Act of 1933 pursuant to a registration statement on Form S-3 (File No. 333-274822) filed with the ~~parties~~Securities and ~~termination~~Exchange ~~provisions.~~Commission Aon ~~copy~~October 2, 2023. The terms of the ~~underwriting~~Company’s ~~agreement~~“at-the-market” isoffering ~~attached~~program asare ~~Exhibit~~described 1in the prospectus supplement, dated August 16, 2024, which supplements the accompanying prospectus, dated October 2, 2023.1 Copies toof ~~this~~the ~~Current~~registration ~~Report~~statement, onprospectus ~~Form~~supplement ~~8-K~~and accompanying prospectus can be accessed through the Securities and ~~incorporated~~Exchange byCommission's ~~reference~~website ~~herein~~at www.sec.gov.

~~The Offering was made pursuant to an effective shelf registration statement (the “Registration Statement”) filed with the Securities and Exchange Commission on October~~ 2, 2023 (File No. 333-274822), a base prospectus, dated October 2, 2023, included as part of the Registration Statement, and a prospectus supplement, dated November 12, 2025, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended. A copy of the opinion of Maples & Calder relating to the issuance of the common shares in the Offering is attached hereto as Exhibit 5.1 to this Current Report on Form 8-K. Exhibits 1.1 and 5.1 hereto are hereby incorporated by reference into the Registration Statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Exhibit Description
1.1						Underwriting Agreement, dated as of November 12, 2025, by and between the Company and J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters.
5.1						Opinion of Maples & Calder.
23.1						Consent of Maples & Calder (included in Exhibit 5.1).
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Biohaven Ltd.
	By:	/s/ Vlad Coric, M.D.
Date: November 13, 2025		Vlad Coric, M.D.
		Chief Executive Officer

Date: January 6, 2026


Biohaven Ltd.

By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

Filing Compare · Biohaven Ltd.